ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0908

Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
Abstract Number: 1530

Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients
Abstract Number: 0937

Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Abstract Number: 1216

Evidence of a Tendency for Localized Recurrence of Arthritis in Rheumatoid Arthritis Patients
Abstract Number: 1887

Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment
Abstract Number: 0028

Evolution of Anti-modified Protein Antibody Responses Can Be Driven by Consecutive Exposure to Different Post-translational Modifications
Abstract Number: 0782

Examining the Association of Socioenvironmental Factors with Depression and Anxiety Symptoms Among Youth with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1214

Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
Abstract Number: 1124

Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Abstract Number: 1001

Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis
Abstract Number: 1009

Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 1436

Expanded PD-1hi CXCR5- HLA-DR+ T Cells Is Associated with Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 1549

Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?
Abstract Number: 1176

Experience from TheMednet: Online Rheumatology Physician Social Network
Abstract Number: 1151

Experiences and Finding Meaning Among Latin Americans Living with Lupus: Learning from Social Media Narratives by Patients and Their Social Network

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].